Colleen Elizabeth Annesley, MD

Colleen Elizabeth Annesley, MD

Cancer and Blood Disorders Center, Leukemia and Lymphoma Program, Apheresis, Immunotherapy Program, Oncology

On staff since September 2015

Children's Title: Medical Director and interim co-Chief Medical Officer, Seattle Children's Therapeutics

Academic Title: Associate Professor, Department of Pediatrics, University of Washington School of Medicine

Research Center: Ben Towne Center for Childhood Cancer Research

"It is inspiring and humbling to work with children, young adults and families in their battle against pediatric cancer. Their bravery and perseverance are the driving force behind finding tomorrow's cure."

  • Biography

    Colleen Annesley, MD, is an attending physician at Seattle Children's Hospital, and an assistant professor in the Department of Pediatrics at the University of Washington. Her clinical areas of interest are leukemia, lymphoma, and high risk or relapsed leukemia.

    My research interests include the development of novel immunotherapy trials for the treatment of pediatric leukemia and lymphoma. CAR T cell immunotherapy has been a ground-breaking treatment for these diseases, and we are now working to improve upon this therapy even further, with the goal of providing a lasting cure for all children with this disease.

  • Patient Testimonials

    Be the first to recommend Colleen Elizabeth Annesley, MD

  • Awards and Honors

    Award Name Award Description Awarded By Award Date
    Recipient, National Institutes of Health Extramural Loan Repayment Program 2013 - 2016
    Selected Participant, AACR Workshop: Molecular Biology in Clinical Oncology 2013
    Department of Pediatrics Teaching Excellence Award University of Miami and Jackson Memorial Hospital 2007

  • Publications

    Other Publications

    • Annesley CE, Summers C, Ceppi F, Gardner RA
      The Evolution and Future of CAR T Cells for B-Cell Acute Lymphoblastic Leukemia.
      29171004 Clinical pharmacology and therapeutics, 2018 April : 103(4)591-598
    • Ceppi F, Rivers J, Annesley C, Pinto N, Park JR, Lindgren C, Mgebroff S, Linn N, Delaney M, Gardner RA
      Lymphocyte apheresis for chimeric antigen receptor T-cell manufacturing in children and young adults with leukemia and neuroblastoma.
      29536556 Transfusion, 2018 Mar 13
    • Gardner RA, Finney O, Annesley C, Brakke H, Summers C, Leger K, Bleakley M, Brown C, Mgebroff S, Kelly-Spratt KS, Hoglund V, Lindgren C, Oron AP, Li D, Riddell SR, Park JR, Jensen MC
      Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults.
      28408462 Blood, 2017 Jun 22 : 129(25)3322-3331 PMCID:PMC5482103
    • Cooper TM, Cassar J, Eckroth E, Malvar J, Sposto R, Gaynon P, Chang BH, Gore L, August K, Pollard JA, DuBois SG, Silverman LB, Oesterheld J, Gammon G, Magoon D, Annesley C, Brown PA
      A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia andamp; Lymphoma (TACL) Study.
      26920889 Clinical cancer research : an official journal of the American Association for Cancer Research, 2016 Aug 15 : 22(16)4014-22
    • Sison EA, Magoon D, Li L, Annesley CE, Romagnoli B, Douglas GJ, Tuffin G, Zimmermann J, Brown P
      POL5551, a novel and potent CXCR4 antagonist, enhances sensitivity to chemotherapy in pediatric ALL.
      26360610 Oncotarget, 2015 Oct 13 : 6(31)30902-18 PMCID:PMC4741576
    • Annesley CE, Brown P
      Novel agents for the treatment of childhood acute leukemia.
      25830014 Therapeutic advances in hematology, 2015 April : 6(2)61-79 PMCID:PMC4365053
    • Sison EA, Magoon D, Li L, Annesley CE, Rau RE, Small D, Brown P
      Plerixafor as a chemosensitizing agent in pediatric acute lymphoblastic leukemia: efficacy and potential mechanisms of resistance to CXCR4 inhibition.
      25333254 Oncotarget, 2014 Oct 15 : 5(19)8947-58 PMCID:PMC4253409
    • Rau R, Magoon D, Greenblatt S, Li L, Annesley C, Duffield AS, Huso D, McIntyre E, Clohessy JG, Reschke M, Pandolfi PP, Small D, Brown P
      NPMc+ cooperates with Flt3/ITD mutations to cause acute leukemia recapitulating human disease.
      24184354 Experimental hematology, 2014 Feb. : 42(2)101-13.e5 PMCID:PMC3932758
    • Annesley CE, Brown P
      The Biology and Targeting of FLT3 in Pediatric Leukemia.
      25295230 Frontiers in oncology, 2014 : 4263 PMCID:PMC4172015

  • Presentations

    Presentation Title Event Location Date
    Wilms tumor 1 (WT1) Mutations Impair Myeloid Differentiation and Cause Myelodysplasia in a Mouse Model". Third Workshop on WT1 Biology Edinburgh, United Kingdom June 2015
    Pediatric Immunotherapy CAR T cells Pediatric Cancer Care: Implications for the Continuum of Rehabilitation Seattle Childrens Hospital Sept. 2017
    Wilms tumor 1 (WT1) Mutations Impair Myeloid Differentiation and Cause Myelodysplasia in a Mouse Model NCI Pediatric Oncology Branch, Research Seminar Series Bethesda, MD Feb. 2015

  • Research Funding

    Grant Title Grantor Amount Award Date
    Pediatric and Young Adult Leukemia Adoptive Therapy (PLAT)-03: A Pilot Feasibility and Safety Study of CD19t T-Antigen Presenting Cells (T-APCs) Following CAR T Cell Immunotherapy for CD19+ Leukemia Clinical Research Scholar Program $140,000.00 Oct 1, 2017 - Sep 30, 2019
    Elucidating the Functional Role of WT1 mutations in leukemogenesis St. Baldricks Foundation $241,392.00 Jul 1, 2012 - Jun 30, 2015

Overview

Board Certification(s)

Pediatrics
Pediatric Hematology-Oncology

Medical/Professional School

Temple University School of Medicine, Philadelphia, PA

Residency

University of Miami Emergency Medicine Residency, Miami, FL

Fellowship

Johns Hopkins University School of Medicine, Baltimore, MD

Research Focus Area

Novel Therapeutics